Carteolol Hydrochloride Solution
NDC 61314-238
Product Information
Carteolol Hydrochloride is a ANDA-approved product labeled by Sandoz Inc. This medication is typically used as a adrenergic beta-antagonists [moa]. It is supplied as a solution for ophthalmic administration. This product entry covers the primary NDC 61314-238 and 3 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 61314-238?
What are the uses of this product?
What are Active Ingredients of this product?
- CARTEOLOL HYDROCHLORIDE 10 mg/mL - A beta-adrenergic antagonist used as an anti-arrhythmia agent, an anti-angina agent, an antihypertensive agent, and an antiglaucoma agent.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- CARTEOLOL HYDROCHLORIDE (UNII: 4797W6I0T4)
- CARTEOLOL (UNII: 8NF31401XG) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7)
- SODIUM CHLORIDE (UNII: 451W47IQ8X)
- SODIUM PHOSPHATE, MONOBASIC, UNSPECIFIED FORM (UNII: 3980JIH2SW)
- SODIUM PHOSPHATE, DIBASIC, UNSPECIFIED FORM (UNII: GR686LBA74)
- SODIUM HYDROXIDE (UNII: 55X04QC32I)
- HYDROCHLORIC ACID (UNII: QTT17582CB)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 978573 - carteolol HCl 1 % Ophthalmic Solution
- RxCUI: 978573 - carteolol hydrochloride 10 MG/ML Ophthalmic Solution
- RxCUI: 978573 - carteolol hydrochloride 1 % Ophthalmic Solution
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.